Sorry, you need to enable JavaScript to visit this website.

MYLOTARG™ (gemtuzumab ozogamicin) Boxed Warning


Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), has been reported in association with the use of MYLOTARG as a single agent, and as part of a combination chemotherapy regimen. Monitor frequently for signs and symptoms of VOD after treatment with MYLOTARG. (5.1 and 6.1)

What's New

No Current Announcements.


Please enter your search term(s) for MYLOTARG™